Comparative effects of Irbesartan on ambulatory and office blood pressure: A substudy of ambulatory blood pressure from the Irbesartan in patients with type 2 diabetes and microalbuminuria study

Diabetes Care

Volumn 26, Issue 3, 2003, Pages 569-574

  Rossing, Kasper ^a   Christensen, Per K ^a   Andersen, Steen ^a   Hovind, Peter ^a   Hansen, Henrik Post ^a   Parving, Hans Henrik ^a,b  

^a STENO DIABETES CENTER   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; INSULIN; IRBESARTAN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; URINALYSIS;

ADULT; AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, RENAL; MALE; MIDDLE AGED; PHYSICIANS' OFFICES; TETRAZOLES;

EID: 0042167336     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.3.569     Document Type: Article

References (16)

1. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pederson O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:1004-1010, 2002
2. Lewis E, Hunsicker L, Bain R, Rhode R: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
3. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
4. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
5. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
6. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000
7. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J: Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 38: E28-E32, 2001
8. Parving H-H, Østerby R, Ritz E: Diabetic nephropathy. In The Kidney. Brenner BM, Levine S, Eds. Philadelphia, WB Saunders, 2000, p. 1731-1773
9. Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B: Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation 103:1869-1874, 2001
10. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS: Urinary albumin excretion: an independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 19:1992-1997, 1999
11. Casiglia E, Zanette G, Mazza A, Donadon V, Donada C, Pizziol A, Tikhonoff V, Palatini P, Pessina AC: Cardiovascular mortality in non-insulin-dependent diabetes mellitus: a controlled study among 683 diabetics and 683 age- and sex-matched normal subjects. Eur J Epidemiol 16:677-684, 2000
12. Garg JP, Bakris GL: Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 7:35-43, 2002
13. White WB, Pickering TG, Morganroth J, James GD, McCabe EJ, Moucha O, Hunter H: A multicenter evaluation of the A&D TM-2420 ambulatory blood pressure recorder. Am J Hypertens 4:890-896, 1991
14. Nielsen FS, Rossing P, Bang LE, Svendsen TL, Gall M-A, Smidt UM, Parving H-H: On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy. Diabetes 44:783-789, 1995
15. Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Mancia G: The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens 16:1685-1691, 1998
16. Nielsen FS, Gaede P, Vedel P, Pedersen O, Parving HH: White coat hypertension in NIDDM patients with and without incipient and overt diabetic nephropathy. Diabetes Care 20:859-863, 1997